Abstract:
Abstract
One of the main components of managing a patient with hypertension is deciding which drug to prescribe
for first-line therapy. This decision should be made primarily on the basis of the best available evidence
of the drug’s ability to prevent adverse health outcomes of the diseases. The objective of this review is to
determine the relative effects of different antihypertensive drugs in reducing the incidence of
cardiovascular outcomes. Articles included in this review were randomized controlled trials and metaanalysis
of RCTs. Relevant articles were obtained from Google scholar database, manual Google search
and reference lists of retrieved article. Titles and abstracts were assessed for relevance and those
potentially fulfilling the inclusion criteria were then assessed in full text. The following main outcomes
were selected: Stroke, myocardial infarction, Coronary heart disease, heart failure, cardiovascular
mortality and cardiovascular morbidity. The evidence in this review shows the newer antihypertensive
drugs (CCBs and ACEIs) are better than conventional antihypertensive drugs in preventing stroke. The
risk of myocardial infarction can be better reduced by using newer antihypertensive drugs like ARBs and
ACEIs. All of the antihypertensive drugs did not have a significant difference in prevention of
cardiovascular mortality. In hypertensive patients who had also diabetics the newer drugs have equal
effectiveness with the conventional once to reduce cardiovascular mortality. The risk of myocardial
infarction in this type of patients is better reduced by using ACEIs than conventional antihypertensive
drugs and CCBs. CCBs are better than ACEIs to reduce the risk of stroke. ARB drugs are better for
diabetic hypertensive patients to prevent cardiovascular mortality and morbidity.
